Le Lézard
Classified in: Health
Subjects: WOM, FDA, DEI

FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat C-Section Pain


PALO ALTO, Calif., July 28, 2022 /PRNewswire/ -- DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been clearedto treat pain following a Caesarean-section (C-section).

Primary Relief, a PENS device, is a significant alternative to opioids for the treatment of pain following a C-section.

The percutaneous electrical nerve stimulator (PENS) system can be used for up to three days for symptomatic relief of post-operative pain following a C-section delivery.

"This device has been shown to make a difference for patients, effectively relieving pain without reliance on opioids or other analgesics. This is a significant advancement in providing options to women," said DyAnsys Chief Executive Srini Nageshwar. "We look forward to connecting with physicians and hospitals to providing this alternative to their patients."

The wearable, battery-operated device is designed to administer periodic low level electrical pulses to the ear over 72 hours from the activation of the device. The electrical pulses are delivered to branches of the cranial nerves on the ear through a wire assembly and stimulation needles.

The effectiveness of the device was demonstrated in a single-center, double arm, randomized, controlled, parallel assignment prospective study involving 44 participants who underwent C-section delivery. The analysis showed that minimally invasive nerve stimulation intervention using Primary Relief device reduced the pain score faster than the standard analgesics. No additional opioid analgesics were required. No complications or adverse events were observed in any of the participants during the study period.

The nonclinical testing of Primary Relief device included biocompatibility testing, electrical safety (electromagnetic compatibility and safety), performance bench testing and software verification and validation.

DyAnsys offers two companion PENS devices - First Relief, with FDA clearance for the treatment of diabetic neuropathic pain, and Drug Relief, with FDA clearance as an aid to drug withdrawal.

DyAnsys Inc. is a global company headquartered in California with subsidiaries in Switzerland and India. DyAnsys provides advanced medical diagnostic and monitoring systems to clinicians in individual practices and hospitals. DyAnsys, ANSiscope. First Relief, Primary Relief and Drug Relief are registered trademarks, of DyAnsys, Inc.

Website: www.dyansys.com   

For more information, contact Srini Nageshwar, (888) 950-4321

SOURCE DyAnsys Inc.


These press releases may also interest you

at 08:15
MGI Tech, a company committed to building core tools and technology to lead life science, is proud to announce that its DNBSEQ-T20x2* gene sequencer has been recognized with a Gold Edison Award in the "Health, Medical & Biotech" category....

at 08:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Company sought an extension of its previously announced stay of proceedings ("Stay") under the Companies' Creditors Arrangement Act (the "CCAA") at a hearing before the Ontario...

at 08:05
This partnership between Vertedge Health Analytics and InHome Connect utilizes data analytics to align patients in value-based care plans with palliative care services, aiming to improve patient care experiences, minimize unnecessary care...

at 08:03
Legacy Medical Consultants (LMC) announces its newest product portfolio addition with the recent Q code approval for Reeva FTtm, a terminally sterilized, full-thickness, dual-layered amnion/chorion allograft designed for covering and protection...

at 08:00
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to...

at 08:00
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...



News published on and distributed by: